Geninus
Geninus, a South Korea-based company, has emerged as a significant player in the precision medicine and genomic data analytics space.
Profile
Geninus provides genomic sequencing and data analytics services to improve rare disease diagnosis and treatment.
Geninus, a South Korea-based company, has emerged as a significant player in the precision medicine and genomic data analytics space. Founded in the early 2010s, Geninus initially focused on providing genomic sequencing services but has since expanded its portfolio to include advanced data analytics tools tailored for healthcare providers and researchers. The company’s flagship product, ExomeDx, offers comprehensive exome sequencing and analysis, while GenomeDx provides genome-wide insights, both aimed at improving rare disease diagnosis and treatment.
Geninus reported $102.3 million in revenue for Q1 2026, marking a 17% year-over-year growth, with exome and genome revenue growing by 27%. The company’s adjusted gross margin remained steady at 69%, though it reported an adjusted net loss of $8.2 million. Geninus has updated its full-year 2026 revenue guidance to $475-$490 million, reflecting strong demand for its services.
The company’s recent strategic moves include launching a reflex product that seamlessly transitions from exome to genome testing when initial results are inconclusive. Geninus has also partnered with CNBC to launch CNBC Cures, a multi-platform initiative aimed at raising awareness for rare diseases. Despite its growth, Geninus faces challenges in scaling its operations and maintaining profitability amidst increasing competition in the genomic data analytics market.
Who buys this
- Healthcare providers
- Research institutions
- Pharmaceutical companies
- Biotech firms
- Patients seeking rare disease diagnosis
Strengths and what to watch
Strengths
- Strong year-over-year revenue growth in exome and genome testing
- High adjusted gross margin of 69%
- Strategic partnerships with major media outlets like CNBC
Watch for
- Adjusted net loss of $8.2 million in Q1 2026
- Increasing competition in the genomic data analytics market
- Challenges in scaling operations while maintaining profitability
Recent moves
Key Information
- Founded
- 2018
- Headquarters
- South Korea
Frequently Asked Questions
What does Geninus do?
Geninus provides genomic sequencing and data analytics services to improve rare disease diagnosis and treatment. The South Korea-based company offers exome and genome sequencing through products like ExomeDx and GenomeDx, serving healthcare providers, researchers, and biotech firms with precision medicine solutions.
How is Geninus performing financially in 2026?
Geninus reported $102.3 million Q1 2026 revenue, a 17% year-over-year growth, with exome/genome revenue up 27%. The company maintains a 69% gross margin but posted an $8.2 million net loss. Full-year guidance was raised to $475-$490 million, reflecting strong service demand.
What are Geninus' main products for genetic testing?
Geninus offers ExomeDx for comprehensive exome sequencing and GenomeDx for genome-wide analysis. Both focus on rare disease diagnosis. Their reflex product automatically upgrades inconclusive exome tests to genome sequencing, providing more definitive results for healthcare providers and researchers.
Who uses Geninus' genomic services?
Geninus serves healthcare providers, research institutions, pharmaceutical companies, biotech firms, and patients seeking rare disease diagnoses. Their genomic sequencing and analytics tools support precision medicine applications across these sectors, particularly for complex diagnostic challenges.
What partnerships has Geninus formed recently?
Geninus partnered with CNBC to launch CNBC Cures, a multi-platform initiative raising rare disease awareness. This follows their strategic focus on expanding market reach through media collaborations while continuing core genomic service development.
What challenges does Geninus face?
Geninus navigates scaling operations while maintaining profitability, evidenced by Q1 2026's $8.2 million net loss despite revenue growth. Competition in genomic data analytics intensifies, requiring continued innovation in sequencing services and diagnostic solutions to retain market position.
Sources
- ir.genedx.com — Q1 2026 financial results and updated full-year guidance
- www.reuters.com — Context on AI integration challenges in the tech industry
- investors.10xgenomics.com — Financial performance context in the genomics industry
- investor.gendigital.com — Financial performance context in the digital health industry